Not Signed In -
Electric And Magnetic Fields |
Cell Phones; Electromagnetic Fields; EMF |
Clinical Trial: Endorectal Coil Magnetic Resonance Images (ERC-MRI)
This study is currently recruiting patients.
Verified by University Health Network, Toronto September 2005
Purpose
When we acquired MR images of the prostate gland using a coil (receiver antenna) inside the rectum, we can see areas with tumour in the prostate gland, and well as details of the anatomy. The coil inside the rectum changes the shape of the prostate gland. In order to use this images to help target radiation therapy to the tumour better, we need to deform the images to the original shape of the prostate gland without the coil. In this study, we will develop a way to deform the images accurately.
| Condition | Intervention | Phase |
|---|---|---|
| Prostatic Neoplasms | Procedure: Endorectal Coil Magnetic Resonance Images | Phase II |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title: Development of a Prostate Deformation Model to Enable Accurate Registration of Endorectal Coil Magnetic Resonance Images (ERC-MRI) to Reference Treatment Planning CT Images
Further Study Details:
Primary Outcomes: The primary aim of this study is to develop a prostate deformation model using the finite element method from anatomic MR images of the prostate gland acquired with and without ERC.
Expected Total Enrollment: 20
Expected Total Enrollment: 20
Study start: February 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Male
Criteria
Inclusion Criteria:
- adenocarcinoma of the prostate
- patient undergoing dose escalated conformal EBRT
- low or intermediate risk prognostic factors: PSA < or equa to20, gleason score <8, T <T3, N category 0 or X, M category 0 or X
- > or equal to 18 years of age
- ECOG performance status 0 or 1
Exclusion Criteria:
- contraindications to MRI
- bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding insertion of fiducial markers
- IFB or collagen vascular disease
- previous colorectal surgery
- previous pelvic RT
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00160953
Cynthia Menard, MD 416-946-2936 cynthia.menard@rmp.uhn.on.ca
Canada, Ontario
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada; Recruiting
Cynthia Menard, MD 416-946-2936 cythia.menard@rmp.uhn.on.ca
Study chairs or principal investigators
Menard Cynthia, MD, Principal Investigator, Princess Margaret Hospital
More Information
Study ID Numbers: UHN REB 05-0041-C
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00160953
Health Authority: Canada: Ethics Review Committee
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00160953
Health Authority: Canada: Ethics Review Committee
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Electric And Magnetic Fields (National Women's Health Information Center)
- EMF (Electric and Magnetic Fields): Questions and Answers (National Institute of Environmental Health Sciences)
email this page
print this page
bookmark this page
feedback on this page
